Jakub Krejcik

Dr. Jakub Krejcik


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JKJakub Krejcik
Jakub Krejcik
MBMike Bogetofte Barnkob
Mike Bogetofte Barnkob
CNCharlotte Guldborg Nyvold
Charlotte Guldborg Nyvold
TLThomas Stauffer Larsen
Thomas Stauffer Larsen
TBTorben Barington
Torben Barington
NANiels Abildgaard
Niels Abildgaard
Multiple myeloma (MM) is a heterogeneous plasma cell malignancy differing substantially in clinical behavior, prognosis, and response to treatment. With the advent of novel therapies, many patients achieve long-lasting remissions, but some experience aggressive and treatment refractory relapses. So far, MM is considered incurable. Myeloma pathogenesis can broadly be explained by two interacting mechanisms, intraclonal evolution of cancer cells and development of an immunosuppressive tumor microenvironment. Failures in isotype class switching and somatic hypermutations result in the neoplastic transformation typical of MM and other B cell malignancies. Interestingly, although genetic alterations occur and evolve over time, they are also present in premalignant stages, which never progress to MM, suggesting that genetic mutations are necessary but not sufficient for myeloma transformation. Changes in composition and function of the immune cells are associated with loss of effective immune surveillance, which might represent another mechanism driving malignant transformation. During the last decade, the traditional view on myeloma treatment has changed dramatically. It is increasingly evident that treatment strategies solely based on targeting intrinsic properties of myeloma cells are insufficient. Lately, approaches that redirect the cells of the otherwise suppressed immune system to take control over myeloma have emerged. Evidence of utility of this principle was initially established by the observation of the graft-versus-myeloma effect in allogeneic stem cell-transplanted patients. A variety of new strategies to harness both innate and antigen-specific immunity against MM have recently been developed and intensively tested in clinical trials. This review aims to give readers a basic understanding of how the immune system can be engaged to treat MM, to summarize the main immunotherapeutic modalities, their current role in clinical care, and future prospects.

Verified
Journal Article
Open access
PDF file
SVSólja Remisdóttir Remisdóttir Veyhe
Sólja Remisdóttir Remisdóttir Veyhe
OCOriane Cédile
Oriane Cédile
SDSara Kamuk Dahlmann
Sara Kamuk Dahlmann
JKJakub Krejcik
Jakub Krejcik
NANiels Abildgaard
Niels Abildgaard
CNCharlotte Guldborg Nyvold
Charlotte Guldborg Nyvold
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B cells due to constitutive B-cell receptor (BCR) signaling, leading to apoptosis resistance and increased proliferation. This study evaluates the effects of the Bruton Tyrosine Kinase (BTK) inhibitor ibrutinib on the molecular composition, clonality, and kinetics of B cells during treatment in CLL patients. Employing a multi-omics approach of up to 3.2 years of follow-up, we analyzed data from 24 CLL patients, specifically focusing on nine patients treated with ibrutinib monotherapy. In this study, clonal stability was observed within the ibrutinib-treated group following an effective initial clinical response, where clonotype frequencies of residual CLL cells remained high and stable, ranging from 74.9% at 1.5 years to 87.7% at approximately 3 years. In contrast, patients treated with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax exhibited substantial reductions in clonal frequencies, approaching molecular eradication. Deep whole-exome sequencing revealed minimal genomic progression in the ibrutinib group, maintaining somatic drivers and variant allele frequencies (VAF) above 0.2 throughout treatment. At the single-cell level, the NF-κB pathway inhibition and apoptotic signals were detected or even augmented during treatment in ibrutinib-treated patients. These findings may corroborate the role of ibrutinib in stabilizing the genomic landscape of CLL cells, preventing significant genomic evolution despite maintaining a high clonal burden within the residual B-cell compartment.

23 April 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JKJakub Krejcik
Jakub Krejcik
ASAnne Marit Sponaas
Anne Marit Sponaas
TMTuna Mutis
Tuna Mutis
Recent phase III studies have demonstrated unprecedented response rates, with high rates of minimal residual disease (MRD) negativity when immunotherapies such as bispecific antibodies or CAR T-cell therapy are used in earlier lines of treatment (2,3). However, treatment-related toxicities remain a significant challenge (4). Given the remarkable efficacy of these therapies-and their potential to cure a subset of patients-it is critically important to better understand and develop strategies to control toxicity and avoid treatment-related morbidity. This is particularly relevant for cellular therapies, which involve living drugs that cannot simply be paused or discontinued once administered.Multiple contributions in this collection focus on adverse events associated with immunotherapies in MM and their management. The article by Zhou et al. highlights several emerging safety concerns related to immunotherapy in MM. At the population level, a pharmacovigilance analysis evaluates adverse events associated with bispecific antibody therapies. Notably, the significant safety signals identified are largely consistent with those reported in prior clinical trials. However, each bispecific antibody also demonstrated several novel safety signals, underscoring the need for continued pharmacovigilance and further investigation in real-world settings as these therapies become more widely used in clinical practice.The next article by Munáriz et al. provides further insight into immune-related toxicities associated with immunotherapy in MM the management of which remains challenging. Among these complications, macrophage activation syndrome-like (MAS-like) toxicity has been increasingly recognized; however, its true incidence remains uncertain due to underreporting and heterogeneous diagnostic criteria. In this context, a multicentre retrospective study conducted by a Spanish group evaluating patients with multiple myeloma treated with an academic anti-BCMA CAR T-cell product offers important insights. In this cohort, 15% of patients met the criteria for MAS-like syndrome, which typically occurred approximately nine days after infusion and was characterized by marked hyperferritinemia, followed by elevations in lactate dehydrogenase (LDH) and hypofibrinogenemia. Importantly, the study also identifies clinical features associated with increased susceptibility to this complication. Patients who developed MAS-like toxicity exhibited more aggressive disease characteristics at baseline and experienced inferior outcomes, including lower complete response rates and shorter progression-free and overall survival. These findings highlight MAS-like toxicity as a clinically relevant and potentially underrecognized complication of CAR T-cell therapy that may also reflect underlying high-risk disease biology. A better understanding of the cellular and molecular mechanism behind this syndrom would also be advantageous.This issue also includes a detailed case report by Phan et al. describing a previously unreported neurological complication associated with CAR T-cell therapy. The authors present a compelling and carefully documented case of severe cerebral vasculopathy ultimately consistent with reversible cerebral vasoconstriction syndrome (RCVS) in a patient treated with CAR T-cell therapy for relapsed/refractory multiple myeloma. The report provides an important discussion on differentiating RCVS from immune effector cellassociated neurotoxicity syndrome (ICANS) and primary central nervous system vasculitis. It expands the spectrum of recognized neurological toxicities associated with CAR T-cell therapy and highlights the importance of thorough diagnostic evaluation in patients presenting with atypical neurological symptoms.As novel CAR targets continue to be developed, the risk of on-target, off-tumor toxicities increases, underscoring the need for controllable CAR T-cell systems. In this context, the article by Bielowski et al. explores potential strategies for regulating circulating CAR T cells without affecting endogenous T cells. One of the approaches was to investigate whether antibody dependent cytotoxicity using antibodies targeting engineered antigens on the CAR product could remove CAR T cells. For example, BCMA-targeting antibody-drug conjugate belantamab mafodotin can selectively eliminate BCMA co-expressing CAR T cells while sparing unmodified T cells. This approach suggests that antibody-drug conjugates may represent a promising strategy for controlling CAR T-cell expansion and managing severe toxicities.Finally, the last two articles in this collection address the important issue of infections during treatment with bispecific antibodies. Traditionally, the increased risk of infection in patients with multiple myeloma has been attributed to impaired function of the residual normal plasma cell population and the associated hypogammaglobulinemia (5). In addition, immunotherapeutic agents used in MM commonly target antigens that are not only expressed by myeloma cells but also by their normal counterparts across different stages of B-cell development (6). As a result, treatment with bispecific antibodies is associated with profound hypogammaglobulinemia and a frequent need for immunoglobulin replacement.The article by Poulsen et al. focuses specifically on the role of immunoglobulin replacement therapy in patients receiving bispecific antibodies. In this systematic review, the authors identified five retrospective, non-randomized cohort studies comprising a total of 653 patients. Three of these studies reported a significant reduction in infections, particularly severe infections, among patients receiving immunoglobulin replacement therapy. Nevertheless, given the considerable time and resource burden associated with continuous immunoglobulin prophylaxis for both patients and healthcare systems, the authors conclude that further prospective randomized studies are needed to confirm these findings...